// App-Quantinova.ai

: Health-Related Quality of Life and Symptoms Among Patients with Relapsed or Refractory AL Amyloidosis Treated with Ixazomib-Dexamethasone Versus Physician's Choice: Results from a Randomized Phase 3 Trial

Researchers

Presenter

  • Vaishali Sanchorawala

Principal Investigators

  • Ashutosh D. Wechalekar

  • Kihyun Kim

  • Stefan Schonland

  • Heather J Landau

  • Kwok Fiona

  • Kenshi Suzuki

  • Angela Dispenzieri

  • Giampaolo Merlini

  • Raymond Comenzo

  • Dasha Cherepanov

  • Vanessa C Hayden

  • Arun Kumar

  • Richard Labotka

  • Douglas V. Faller

  • Efstathios Kastritis

Medical Centers

  • Division of Hematology-Oncology, Department of Medicine, Sungkyunkwan Univ. Sch. of Med. Samsung Medical Center, Seoul, South Korea

  • Amyloidosis Center, IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy

  • Amyloidosis Center, Boston University School of Medicine and Boston Medical Center, Boston, MA

  • Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece

  • National Amyloidosis Centre, University College London, London, United Kingdom

  • Mayo Clinic, Rochester, MN

  • Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

  • Division of Hematology/Oncology, John C. Davis Myeloma and Amyloid Program, Tufts Medical Center, Boston, MA

  • Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan

  • Department of Haematology, Westmead Hospital, Canberra, Australia

  • Medical Department V, Amyloidosis Center, Heidelberg University Hospital, Heidelberg, Germany

Locations

  • Republic of South Korea

  • United States

  • Italy

  • Japan

  • Greece

  • Australia

  • United Kingdom

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • AL Amyloidosis

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Ixazomib

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved